Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Sage Therapeutics's share price for the quarter that ended in Mar. 2024 was $18.74. Sage Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 60.18 Mil. Therefore, Sage Therapeutics's market cap for the quarter that ended in Mar. 2024 was $1,127.81 Mil.
Sage Therapeutics's quarterly market cap
increased
from Sep. 2023 ($1,234.13 Mil) to Dec. 2023 ($1,301.14 Mil) but then
declined
from Dec. 2023 ($1,301.14 Mil) to Mar. 2024 ($1,127.81 Mil).
Sage Therapeutics's annual market cap
declined
from Dec. 2021 ($2,507.18 Mil) to Dec. 2022 ($2,269.68 Mil) and
declined
from Dec. 2022 ($2,269.68 Mil) to Dec. 2023 ($1,301.14 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sage Therapeutics's Enterprise Value for Today is $-8.98 Mil.
Sage Therapeutics Market Cap Historical Data
The historical data trend for Sage Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sage Therapeutics's Market Cap
For the Biotechnology subindustry, Sage Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sage Therapeutics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sage Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Sage Therapeutics's Market Cap falls into.
Sage Therapeutics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Sage Therapeutics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sage Therapeutics (NAS:SAGE) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sage Therapeutics Market Cap Related Terms
Thank you for viewing the detailed overview of Sage Therapeutics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Sage Therapeutics (Sage Therapeutics) Business Description
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. The GABA receptor family, which is recognized as the inhibitory neurotransmitter in the CNS, mediates downstream neurologic and bodily function via activation of GABAA receptors. The NMDA-type receptors of the glutamate receptor system are a excitatory receptor system in the CNS. Dysfunction in these systems is implicated in a broad range of CNS disorders.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SAGE has been successfully added to your 